Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegia

Archives of Neurology

Volumn 69, Issue 4, 2012, Pages 500-508

  Du Montcel, Sophie Tezenas ^a,c   Charles, Perrine ^a   Goizet, Cyril ^a,f,g   Marelli, Cecilia ^a,b,d,e   Ribai, Pascale ^a   Vincitorio, Carlo ^a   Anheim, Mathieu ^a   Guyant Maréchal, Lucie ^a,i   Le Bayon, Alice ^a,h   Vandenberghe, Nadia ^a,j   Tchikviladzé, Maya ^a   Devos, David ^a,k   Le Ber, Isabelle ^a,b,d,e   N'Guyen, Karine ^a,l   Cazeneuve, Cécile ^a   Tallaksen, Chantal ^a,b,d,e   Brice, Alexis ^a,b,d,e   Durr, Alexandra ^a,b,d,e  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^c Modelling in Clinical Research   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e CNRS   (France)

^f HÔPITAL PELLEGRIN   (France)

^g UNIVERSITÉ DE BORDEAUX   (France)

^h DEPARTMENT OF NEUROLOGY   (France)

ⁱ ROUEN UNIVERSITY HOSPITAL   (France)

^j HÔPITAL NEUROLOGIQUE   (France)

^k UNIV LILLE   (France)

^l TIMONE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

POLYGLUTAMINE;

ADULT; ALLELE; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CEREBELLAR ATAXIA; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSTONIA; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; INSTRUMENT VALIDATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARKINSONISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCA1 GENE; SCA2 GENE; SCA3 GENE; SCA7 GENE; SCORING SYSTEM; SPASTIC PARAPLEGIA; SPASTICITY;

ADULT; AGED; CEREBELLAR ATAXIA; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FRANCE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PARAPLEGIA; PEPTIDES; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; WRITING; YOUNG ADULT;

EID: 84859974906     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.2713     Document Type: Article

References (24)

1. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 2010;9(9):885-894.
2. Stevanin G, Camuzat A, Holmes SE, et al. CAG/CTG repeat expansions at the Huntington's disease-like 2 locus are rare in Huntington's disease patients. Neurology. 2002;58(6):965-967. (Pubitemid 34242078)
3. Stevanin G, Brice A. Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4). Cerebellum. 2008;7(2):170-178.
4. Yamada M, Sato T, Tsuji S, Takahashi H. CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol. 2008; 115(1):71-86. (Pubitemid 350238668)
5. Schöls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004;3(5):291-304.
6. Soong BW, Paulson HL. Spinocerebellar ataxias: an update. Curr Opin Neurol. 2007;20(4):438-446. (Pubitemid 47051992)
7. Schmitz-Hübsch T, du Montcel ST, Baliko L, et al. Scale for the Assessment and Rating of Ataxia: development of a new clinical scale [published correction appears in Neurology. 2006;67(2):299]. Neurology. 2006;66(11):1717-1720.
8. Jardim LB, Hauser L, Kieling C, et al. Progression rate of neurological deficits in a 10-year cohort of SCA3 patients. Cerebellum. 2010;9(3):419-428.
9. du Montcel ST, Charles P, Ribai P, et al. Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment. Brain. 2008; 131(pt 5):1352-1361.
10. Chan E, Charles P, Ribai P, et al. Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias. Mov Disord. 2011;26(3):534-538.
11. Schmitz-Hübsch T, Fimmers R, Rakowicz M, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology . 2010;74(8):678-684.
12. Hazan J, Davoine CS, Mavel D, et al. A fine integrated map of the SPG4 locus excludes an expanded CAG repeat in chromosome 2p-linked autosomal dominant spastic paraplegia. Genomics. 1999;60(3):309-319. (Pubitemid 29471498)
13. Fonknechten N, Mavel D, Byrne P, et al. Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia [published correction appears in Hum Mol Genet. 2005;14(3):461]. Hum Mol Genet. 2000;9(4):637-644. (Pubitemid 30154022)
14. Depienne C, Stevanin G, Brice A, Durr A. Hereditary spastic paraplegias: an update. Curr Opin Neurol. 2007;20(6):674-680. (Pubitemid 350085009)
15. Schmitz-Hübsch T, Coudert M, Bauer P, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology. 2008;71(13):982-989.
16. Jacobi H, Bauer P, Giunti P, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology. 2011;77(11):1035-1041.
17. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(pt 5):871-882. (Pubitemid 29219261)
18. Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology. 2010;74(10):839-845.
19. Klockgether T, Lüdtke R, Kramer B, et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain. 1998;121(pt 4):589-600.
20. Dürr A, Stevanin G, Cancel G, et al. Spinocerebellar ataxia 3 and Machado- Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol. 1996;39(4):490-499.
21. Maschke M, Oehlert G, Xie TD, et al. Clinical feature profile of spinocerebellar ataxia type 1-8 predicts genetically defined subtypes. Mov Disord. 2005;20(11):1405-1412. (Pubitemid 43072647)
22. França MC Jr, D'Abreu A, Nucci A, Cendes F, Lopes-Cendes I. Progression of ataxia in patients with Machado-Joseph disease. Mov Disord. 2009;24(9):1387-1390.
23. Charles P, Camuzat A, Benammar N, et al French Parkinson's Disease Genetic Study Group. Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism? Neurology. 2007;69(21):1970-1975. (Pubitemid 350145088)
24. Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466(7310):1069-1075.